<DOC>
	<DOCNO>NCT00149981</DOCNO>
	<brief_summary>Facilitated access everolimus commercially available reimbursable appropriate party</brief_summary>
	<brief_title>A Facilitated Access Program Provide Everolimus ( RAD ) Maintenance Patients Completing Therapy RAD Trials Solid Organ Transplantation</brief_title>
	<detailed_description>This treatment protocol design provide access everolimus ( RAD ) maintenance immunosuppression . The objective facilitate management patient maintenance immunosuppression therapy complete everolimus trial , - To provide everolimus maintenance therapy access program - To collect review safety data 120 month project discontinue whichever come first . - To collect review safety data 120 month Certican commercially available give indication reimburse appropriate payors project discontinue whichever come first .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male female recipient solid organ transplant Subject currently enrol everolimus ( RAD ) trial sponsor Novartis Currently investigational drug everolimus ( RAD ) therapy Inability unwillingness comply immunosuppressive regimen . Pregnancy . History acute organ rejection within last 3 month . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Kidney , heart , lung , liver , pancreas</keyword>
</DOC>